13,556 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the fourth quarter, Holdings Channel.com reports. The firm bought 13,556 shares of the biotechnology company’s stock, valued at approximately $443,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARWR. Washington Trust Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $25,000. Fifth Third Bancorp raised its stake in shares of Arrowhead Pharmaceuticals by 112.0% during the 3rd quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Arrowhead Pharmaceuticals by 96.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 1,352 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 130.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,270 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,980 shares during the last quarter. Finally, EP Wealth Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 851.8% during the 3rd quarter. EP Wealth Advisors LLC now owns 8,500 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 7,607 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 6.1 %

ARWR stock opened at $21.87 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $42.48. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -7.87 and a beta of 0.71. The business’s 50-day moving average is $28.28 and its 200 day moving average is $28.88.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The firm had revenue of $3.55 million during the quarter, compared to analyst estimates of $35.60 million. During the same quarter in the previous year, the firm posted ($0.39) earnings per share. The company’s quarterly revenue was down 94.3% on a year-over-year basis. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 57,499 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total value of $1,860,092.65. Following the sale, the chief executive officer now directly owns 3,715,048 shares in the company, valued at approximately $120,181,802.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total value of $1,407,600.00. Following the transaction, the chief financial officer now directly owns 400,600 shares of the company’s stock, valued at approximately $14,097,114. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Richard Anzalone sold 57,499 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total transaction of $1,860,092.65. Following the completion of the transaction, the chief executive officer now directly owns 3,715,048 shares in the company, valued at $120,181,802.80. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on ARWR shares. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, February 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Citigroup raised their target price on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $53.45.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.